Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04191824 · ClinicalTrials.gov registry record · NA
Genetic Testing to Understand and Address Renal Disease Disparities Across the United States
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 6,789
- Enrollment target
NCT04191824: Completed NA study, sponsored by Duke University.
NCT04191824 is a NA study that has completed, run by Duke University. The registered enrollment target is 6,789 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (384% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04191824, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 6,789 participants
- Enrollment target
Study Summary
GUARDD-US is a prospective, multicenter, unblinded, two arm randomized pragmatic clinical trial. Participants will be randomized in a 1:1 ratio to immediate APOL1 gene testing and return of results (ROR) to participant and provider (Intervention arm) versus delayed APOL1 gene testing and ROR to participant and provider (Control arm). The main study will compare outcomes between APOL1 positive participants in the Intervention arm (i.e., early knowledge of APOL1 status) to APOL1 positive participants in the Control arm (i.e., delayed knowledge of APOL1 status). Participants that are APOL1 negative in the Intervention and Control groups will not be included in the main study analyses. GUARDD-US also includes a substudy to determine the effect of knowledge of genetic test results that predict efficacy of various antihypertensive medications on change in SBP from baseline to 3 months in APOL1 negative individuals at participating sites. This substudy is listed separately on clinicaltrials.gov as NCT06748040 and Unique Protocol ID - PRO00102997\_A
Interventions
- OTHER Timing of return of results
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,789 participants |
| Start Date | 2020-07-10 |
| Est. Completion | 2024-05-17 |
| Phase | NA |
What the finished NCT04191824 record still lists
NCT04191824 is an interventional study that assigns participants to a tested intervention. Its 6,789 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (384% higher).
The record links to 0 conditions, and to 1 intervention - of which Timing of return of results is the first listed.
NCT04191824 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04191824 about?
NCT04191824 is a clinical study titled "Genetic Testing to Understand and Address Renal Disease Disparities Across the United States". GUARDD-US is a prospective, multicenter, unblinded, two arm randomized pragmatic clinical trial. Participants will be randomized in a 1:1 ratio to immediate APOL1 gene testing and return of results (ROR) to participant and provider (Intervention arm) versus delayed APOL1 gene testing and ROR to part...
What is the current status of trial NCT04191824?
This trial is currently completed. It is a NA study. The enrollment target is 6,789 participants. The study started on 2020-07-10. Estimated completion is 2024-05-17.
What interventions are being tested in trial NCT04191824?
The interventions under investigation include: Timing of return of results (OTHER).
Who is sponsoring clinical trial NCT04191824?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04191824's enrollment target sits among peer trials
6,789 21st of 2000 higher than 1,980 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03887715 · 6,800 participants · NA
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
- NCT06234384 · 6,833 participants
Foundation for Sarcoidosis Research Advanced Cures Registry (FSR-SARC Registry)
- NCT05121324 · 6,700 participants · Phase 3
Pediatric Dose Optimization for Seizures in Emergency Medical Services
- NCT06272045 · 6,618 participants · NA
Early Intervention to Promote Cardiovascular Health of Mothers and Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI